Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

The adjuvant GLA-AF enhances human intradermal vaccine responses.

Carter D, van Hoeven N, Baldwin S, Levin Y, Kochba E, Magill A, Charland N, Landry N, Nu K, Frevol A, Ashman J, Sagawa ZK, Beckmann AM, Reed SG.

Sci Adv. 2018 Sep 12;4(9):eaas9930. doi: 10.1126/sciadv.aas9930. eCollection 2018 Sep.

2.

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG; TBVPX-113 Study Team.

NPJ Vaccines. 2018 Sep 4;3:34. doi: 10.1038/s41541-018-0057-5. eCollection 2018.

3.

A Fluorescent-Labeled Phosphono Bisbenzguanidine As an Activity-Based Probe for Matriptase.

Häußler D, Schulz-Fincke AC, Beckmann AM, Keils A, Gilberg E, Mangold M, Bajorath J, Stirnberg M, Steinmetzer T, Gütschow M.

Chemistry. 2017 Apr 19;23(22):5205-5209. doi: 10.1002/chem.201700319. Epub 2017 Mar 28.

PMID:
28370501
4.

Evaluation of bisbenzamidines as inhibitors for matriptase-2.

Beckmann AM, Gilberg E, Gattner S, Huang TL, Vanden Eynde JJ, Mayence A, Bajorath J, Stirnberg M, Gütschow M.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3741-5. doi: 10.1016/j.bmcl.2016.05.071. Epub 2016 May 26.

PMID:
27287367
5.

The intact Kunitz domain protects the amyloid precursor protein from being processed by matriptase-2.

Beckmann AM, Glebov K, Walter J, Merkel O, Mangold M, Schmidt F, Becker-Pauly C, Gütschow M, Stirnberg M.

Biol Chem. 2016 Aug 1;397(8):777-90. doi: 10.1515/hsz-2015-0263.

PMID:
27078672
6.

3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach.

Roydeva PG, Beckmann AM, Stirnberg M, Cesar J, Kikelj D, Ilaš J, Gütschow M.

Pharmaceuticals (Basel). 2016 Jan 13;9(1). pii: E2. doi: 10.3390/ph9010002.

7.

En Route to New Therapeutic Options for Iron Overload Diseases: Matriptase-2 as a Target for Kunitz-Type Inhibitors.

Beckmann AM, Maurer E, Lülsdorff V, Wilms A, Furtmann N, Bajorath J, Gütschow M, Stirnberg M.

Chembiochem. 2016 Apr 1;17(7):595-604. doi: 10.1002/cbic.201500651. Epub 2016 Feb 16.

PMID:
26762582
8.

3-Cyano-3-aza-β-amino Acid Derivatives as Inhibitors of Human Cysteine Cathepsins.

Schmitz J, Beckmann AM, Dudic A, Li T, Sellier R, Bartz U, Gütschow M.

ACS Med Chem Lett. 2014 Aug 11;5(10):1076-81. doi: 10.1021/ml500238q. eCollection 2014 Oct 9.

9.

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis.

Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM.

Vaccine. 2011 Apr 27;29(19):3531-7. doi: 10.1016/j.vaccine.2011.02.096. Epub 2011 Mar 15.

PMID:
21414377
10.

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis.

Llanos-Cuentas A, Calderón W, Cruz M, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Bertholet S, Laughlin EM, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM.

Vaccine. 2010 Oct 28;28(46):7427-35. doi: 10.1016/j.vaccine.2010.08.092. Epub 2010 Sep 17.

PMID:
20851080
11.

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.

Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Pine SO, Cowgill KD, Reed SG, Piazza FM.

Vaccine. 2010 Sep 14;28(40):6581-7. doi: 10.1016/j.vaccine.2010.07.063. Epub 2010 Aug 3.

PMID:
20688040
12.

Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis.

Vélez ID, Gilchrist K, Martínez S, Ramírez-Pineda JR, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM.

Vaccine. 2009 Dec 11;28(2):329-37. doi: 10.1016/j.vaccine.2009.10.045. Epub 2009 Oct 30.

PMID:
19879995
13.

Glutamate-mediated transmission, alcohol, and alcoholism.

Dodd PR, Beckmann AM, Davidson MS, Wilce PA.

Neurochem Int. 2000 Nov-Dec;37(5-6):509-33. Review.

PMID:
10871702
14.

Sequential increase in Egr-1 and AP-1 DNA binding activity in the dentate gyrus following the induction of long-term potentiation.

Williams JM, Beckmann AM, Mason-Parker SE, Abraham WC, Wilce PA, Tate WP.

Brain Res Mol Brain Res. 2000 May 5;77(2):258-66.

PMID:
10837920
15.

Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine.

Kelz MB, Chen J, Carlezon WA Jr, Whisler K, Gilden L, Beckmann AM, Steffen C, Zhang YJ, Marotti L, Self DW, Tkatch T, Baranauskas G, Surmeier DJ, Neve RL, Duman RS, Picciotto MR, Nestler EJ.

Nature. 1999 Sep 16;401(6750):272-6.

PMID:
10499584
16.

Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection.

Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao EJ, Fitzgibbons ED, Huang S, Beckmann AM, McDougall JK, Galloway DA.

J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36.

PMID:
9811312
17.
18.

Differential expression of Egr-1-like DNA-binding activities in the naive rat brain and after excitatory stimulation.

Beckmann AM, Davidson MS, Goodenough S, Wilce PA.

J Neurochem. 1997 Dec;69(6):2227-37.

19.

Cofactors with human papillomavirus in a population-based study of vulvar cancer.

Madeleine MM, Daling JR, Carter JJ, Wipf GC, Schwartz SM, McKnight B, Kurman RJ, Beckmann AM, Hagensee ME, Galloway DA.

J Natl Cancer Inst. 1997 Oct 15;89(20):1516-23. Erratum in: J Natl Cancer Inst 1997 Dec 17;89(24):1896.

PMID:
9337348
20.

Egr transcription factors in the nervous system.

Beckmann AM, Wilce PA.

Neurochem Int. 1997 Oct;31(4):477-510; discussion 517-6. Review.

PMID:
9307998
21.

AP-1 and Egr DNA-binding activities are increased in rat brain during ethanol withdrawal.

Beckmann AM, Matsumoto I, Wilce PA.

J Neurochem. 1997 Jul;69(1):306-14.

22.

Human papillomavirus type 16 DNA in esophageal carcinomas from Alaska Natives.

Miller BA, Davidson M, Myerson D, Icenogle J, Lanier AP, Tan J, Beckmann AM.

Int J Cancer. 1997 Apr 10;71(2):218-22.

23.

Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women.

Huang S, Afonina I, Miller BA, Beckmann AM.

Int J Cancer. 1997 Feb 7;70(4):408-11.

24.

Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States.

Burt RD, Vaughan TL, McKnight B, Davis S, Beckmann AM, Smith AG, Nisperos B, Swanson GM, Berwick M.

Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):879-87.

25.

The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection.

Daling JR, Madeleine MM, McKnight B, Carter JJ, Wipf GC, Ashley R, Schwartz SM, Beckmann AM, Hagensee ME, Mandelson MT, Galloway DA.

Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):541-8.

26.

Loss of the adenomatous polyposis coli gene and human papillomavirus infection in oral carcinogenesis.

Mao EJ, Oda D, Haigh WG, Beckmann AM.

Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):260-3.

PMID:
8776423
27.

Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia.

Mao EJ, Schwartz SM, Daling JR, Oda D, Tickman L, Beckmann AM.

Int J Cancer. 1996 Apr 22;69(2):152-8.

28.

Immediate early gene expression during morphine withdrawal.

Beckmann AM, Matsumoto I, Wilce PA.

Neuropharmacology. 1995 Sep;34(9):1183-9.

PMID:
8532189
29.

Elevated AP-1 DNA-binding activity in rat brain during ethanol withdrawal.

Beckmann AM, Matsumoto I, Wilce PA.

Alcohol Alcohol Suppl. 1994;2:223-7.

PMID:
8974340
30.

Sequence variation in the noncoding region of human papillomavirus type 16 detected by single-strand conformation polymorphism analysis.

Xi LF, Demers W, Kiviat NB, Kuypers J, Beckmann AM, Galloway DA.

J Infect Dis. 1993 Sep;168(3):610-7.

PMID:
8394860
31.

History of circumcision, medical conditions, and sexual activity and risk of penile cancer.

Maden C, Sherman KJ, Beckmann AM, Hislop TG, Teh CZ, Ashley RL, Daling JR.

J Natl Cancer Inst. 1993 Jan 6;85(1):19-24.

PMID:
8380060
32.

A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB.

N Engl J Med. 1992 Oct 29;327(18):1272-8.

33.

Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men.

Maden C, Beckmann AM, Thomas DB, McKnight B, Sherman KJ, Ashley RL, Corey L, Daling JR.

Am J Epidemiol. 1992 May 15;135(10):1093-102.

PMID:
1321561
34.

Cigarette smoking and the risk of anogenital cancer.

Daling JR, Sherman KJ, Hislop TG, Maden C, Mandelson MT, Beckmann AM, Weiss NS.

Am J Epidemiol. 1992 Jan 15;135(2):180-9.

PMID:
1311142
35.

Genital-type human papillomavirus infection is not associated with surface epithelial ovarian carcinoma.

Beckmann AM, Sherman KJ, Saran L, Weiss NS.

Gynecol Oncol. 1991 Dec;43(3):247-51.

PMID:
1661263
36.

Human papillomavirus infection in women with multicentric squamous cell neoplasia.

Beckmann AM, Acker R, Christiansen AE, Sherman KJ.

Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1431-7.

PMID:
1659785
37.

Comparative virologic studies of condylomata acuminata reveal a lack of dual infections with human papillomaviruses.

Beckmann AM, Sherman KJ, Myerson D, Daling JR, McDougall JK, Galloway DA.

J Infect Dis. 1991 Feb;163(2):393-6.

PMID:
1846393
38.

Evidence of prevalent genital-type human papillomavirus infections in adults and children.

Jenison SA, Yu XP, Valentine JM, Koutsky LA, Christiansen AE, Beckmann AM, Galloway DA.

J Infect Dis. 1990 Jul;162(1):60-9.

PMID:
2162371
39.

Presence of human papillomavirus deoxyribonucleic acid.

Beckmann AM, Myerson D, McDougall JK.

Am J Obstet Gynecol. 1989 Nov;161(5):1419-20. No abstract available.

PMID:
2556032
40.

Human papillomavirus infection and anal cancer.

Beckmann AM, Daling JR, Sherman KJ, Maden C, Miller BA, Coates RJ, Kiviat NB, Myerson D, Weiss NS, Hislop TG, et al.

Int J Cancer. 1989 Jun 15;43(6):1042-9.

PMID:
2543642
41.

Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic.

Kiviat NB, Koutsky LA, Paavonen JA, Galloway DA, Critchlow CW, Beckmann AM, McDougall JK, Peterson ML, Stevens CE, Lipinski CM, et al.

J Infect Dis. 1989 Feb;159(2):293-302.

PMID:
2536781
42.
43.

Human papillomavirus type 16 in multifocal neoplasia of the female genital tract.

Beckmann AM, Kiviat NB, Daling JR, Sherman KJ, McDougall JK.

Int J Gynecol Pathol. 1988;7(1):39-47.

PMID:
2832336
44.

Methods for diagnosing papillomavirus infection.

McDougall JK, Beckmann AM, Kiviat NB.

Ciba Found Symp. 1986;120:86-103. Review.

PMID:
3013528
45.

Detection of viral DNA and RNA by in situ hybridization.

McDougall JK, Myerson D, Beckmann AM.

J Histochem Cytochem. 1986 Jan;34(1):33-8.

PMID:
3001177
46.

Detection and localization of human papillomavirus DNA in human genital condylomas by in situ hybridization with biotinylated probes.

Beckmann AM, Myerson D, Daling JR, Kiviat NB, Fenoglio CM, McDougall JK.

J Med Virol. 1985 Jul;16(3):265-73.

PMID:
2993496
47.
48.

Genetic heterogeneity of the human papovaviruses BK and JC.

Beckmann AM, Shah KV, Mounts P.

J Med Virol. 1985 Mar;15(3):239-50.

PMID:
2984326
49.

HSV, CMV, and HPV in human neoplasia.

McDougall JK, Nelson JA, Myerson D, Beckmann AM, Galloway DA.

J Invest Dermatol. 1984 Jul;83(1 Suppl):72s-76s. Review.

50.

Propagation and primary isolation of JCV and BKV in urinary epithelial cell cultures.

Beckmann AM, Shah KV.

Prog Clin Biol Res. 1983;105:3-14.

PMID:
6304767

Supplemental Content

Loading ...
Support Center